Biology of Blood and Marrow Transplantation
Volume 11, Issue 11 , Pages 862-870 , November 2005

Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005

  • Linda M. Griffith

      Affiliations

    • L.M.G, S.Z.P., and R.A.N. contributed equally to this work.
    • Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
    • Corresponding Author InformationCorrespondence and reprint requests: Steven Z. Pavletic, MD, Experimental Transplantation and Immunology Branch, National Cancer Institute, WG Magnuson Clinical Center, 10 Center Dr., CRC/Room 4-3130, Bethesda, MD 20892-1203
    • ,
  • Steven Z. Pavletic

      Affiliations

    • Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Alan Tyndall

      Affiliations

    • Department of Rheumatology, Felix-Platter Spital, Basel, Switzerland
    • ,
  • Christopher N. Bredeson

      Affiliations

    • Center for International Blood and Marrow Transplantation Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • James D. Bowen

      Affiliations

    • Department of Neurology, University of Washington, Seattle, Washington
    • ,
  • Richard W. Childs

      Affiliations

    • Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • Alois Gratwohl

      Affiliations

    • Departments of Hematology and Internal Medicine, University of Basel, Kantonsspital, Basel, Switzerland
    • ,
  • Jacob M. van Laar

      Affiliations

    • Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • Maureen D. Mayes

      Affiliations

    • Division of Rheumatology, Department of Medicine, University of Texas-Houston Health Science Center, Houston, Texas
    • ,
  • Roland Martin

      Affiliations

    • Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
    • ,
  • Peter A. McSweeney

      Affiliations

    • Blood and Marrow Transplant Program, Presbyterian/St. Luke’s Medical Center, Rocky Mountain Cancer Center, Denver, Colorado
    • ,
  • Paolo A. Muraro

      Affiliations

    • Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
    • ,
  • Harry Openshaw

      Affiliations

    • Department of Neurology, City of Hope National Medical Center, Duarte, California
    • ,
  • Riccardo Saccardi

      Affiliations

    • Bone Marrow Transplant Unit, UO Ematologia, Policlinico Careggi, Florence, Italy
    • ,
  • Brenda M. Sandmaier

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, and University of Washington, Seattle, Washington
    • ,
  • Stephen J. Forman

      Affiliations

    • Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California
    • ,
  • Richard A. Nash

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, and University of Washington, Seattle, Washington
    • L.M.G, S.Z.P., and R.A.N. contributed equally to this work.
    • ,
  • workshop participants

Received 13 July 2005 ,Accepted 14 July 2005.

References 

  1. Armitage JO . Bone marrow transplantation . N Engl J Med . 1994;330:827–838
  2. Horowitz MM . Uses and growth of hematopoietic cell transplantation . In:  Blume KG ,  Forman SJ ,  Appelbaum FR editor. Thomas’ Hematopoietic Cell Transplantation . 3rd ed.. Malden, MA: Blackwell; 2004;p. 9–15
  3. van Bekkum DW . Preclinical experiments . Best Pract Res Clin Haematol . 2004;17:201–222
  4. Doney K , Leisenring W , Storb R , Appelbaum FR . Primary treatment of acquired aplastic anemia. Outcomes with bone marrow transplantation and immunosuppressive therapy . Ann Intern Med . 1997;126:107–115
  5. Deeg HJ , Leisenring W , Storb R , et al.   Long-term outcome after marrow transplantation for severe aplastic anemia . Blood . 1998;91:3637–3645
  6. Ades L , Mary JY , Robin M , et al.   Long-term outcome after bone marrow transplantation for severe aplastic anemia . Blood . 2004;103:2490–2497
  7. Nelson JL , Torrez R , Louie FM , Choe OS , Storb R , Sullivan KM . Pre-existing autoimmune disease in patients with longterm survival after allogeneic bone marrow transplantation . J Rheumatol . 1997;24(suppl 48):23–29
  8. Marmot AM . Coincidental autoimmune disease in patients transplanted for conventional indications . Best Pract Res Clin Haematol . 2004;17:223–232
  9. Lopez-Cubero SO , Sullivan KM , McDonald GB . Course of Crohn’s disease after allogeneic marrow transplantation . Gastroenterology . 1998;114:433–440
  10. Mandalfino P , Rice G , Smith A , Klein JL , Rystedt L , Ebers GC . Bone marrow transplantation in multiple sclerosis . J Neurol . 2000;247:691–695
  11. Khorshid O , Hosing C , Bibawi S , et al.   Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus . J Rheumatol . 2004;31:2513–2516
  12. Burt RK , Oyama Y , Verda L , et al.   Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism . Arthritis Rheum . 2004;50:2466–2470
  13. McKendry RJ , Huebsch L , Leclair B . Progression of rheumatoid arthritis following bone marrow transplantation (A case report with a 13-year follow up) . Arthritis Rheum . 1996;39:1246–1253
  14. Gratwohl A , Passweg J , Bocelli-Tyndall C , et al.   Autologous hematopoietic stem cell transplantation for autoimmune diseases . Bone Marrow Transplant . 2005;35:869–879
  15. Hakim FT , Memon SA , Cepeda R , et al.   Age-dependent incidence, time course, and consequences of thymic renewal in adults . J Clin Invest . 2005;115:930–939
  16. Storek J , Zhao Z , Lin E , et al.   Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases) . Clin Immunol . 2004;113:285–298
  17. Sykes M , Nikolic B . Treatment of severe autoimmune disease by stem-cell transplantation . Nature . 2005;435:620–627
  18. Muraro PA , Douek DA , Packer A , et al.   Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients . J Exp Med . 2005;201:805–816
  19. Bielekova B , Martin R . Development of biomarkers in multiple sclerosis . Brain . 2004;127:1463–1478
  20. Illei GG , Tackey E , Lapteva L , Lipsky PE . Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability . Arthritis Rheum . 2004;50:1709–1720
  21. Illei GG , Tackey E , Lapteva L , Lipsky PE . Biomarkers in systemic lupus erythematosus. II. Markers of disease activity . Arthritis Rheum . 2004;50:2048–2065
  22. Diaconescu R , Flowers CR , Storer B , et al.   Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors . Blood . 2004;104:1550–1558
  23. Storb R , Etzioni R , Anasetti C , et al.   Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia . Blood . 1994;84:941–949
  24. Storb R , Blume KG , O’Donnell MR , et al.   Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations (the experience in four centers) . Biol Blood Marrow Transplant . 2001;7:39–44
  25. Childs R , Clave E , Contentin N , et al.   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation (full donor T-cell chimerism precedes alloimmune responses) . Blood . 1999;94:3234–3241
  26. McSweeney PA , Niederwieser D , Shizuru JA , et al.   Hematopoietic cell transplantation in older patients with hematologic malignancies (replacing high-dose cytotoxic therapy with graft-versus-tumor effects) . Blood . 2001;97:3390–3400
  27. Niederwieser D , Maris M , Shizuru JA , et al.   Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases . Blood . 2003;101:1620–1629
  28. Or R , Shapira MY , Resnick I , et al.   Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase . Blood . 2003;101:441–445
  29. Morris E , Thomson K , Craddock C , et al.   Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma . Blood . 2004;104:3865–3871
  30. Djulbegovic B , Seidenfeld J , Bonnell C , Kumar A . Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies (a systematic review) . Cancer Control . 2003;10:17–41
  31. Confavreux C , Vuksic S , Moreau T , Adeline P . Relapses and progression of disability in multiple sclerosis . N Engl J Med . 2000;343:1430–1438
  32. Bronnum-Hansen H , Koch-Henriksen H , Stenager E . Trends in survival and cause of death in Danish patients with multiple sclerosis . Brain . 2004;127:844–850
  33. Bryan C , Knight C , Black CM , Silman AJ . Prediction of five-year survival following presentation with scleroderma (development of a simple model using three disease factors at first visit) . Arthritis Rheum . 1999;42:2660–2665
  34. Steen VD , Medsger TA . Severe organ involvement in systemic sclerosis with diffuse scleroderma . Arthritis Rheum . 2000;43:2437–2444
  35. Sullivan KM . Longterm followup and quality of life after hematopoietic cell transplantation . J Rheumatol . 1997;24(suppl 48):46–52
  36. Socie G , Stone JV , Wingard JR , et al.   Long-term survival and late deaths after allogeneic bone marrow transplantation . N Engl J Med . 1999;341:14–21
  37. Kodish E , Lantos J , Stocking C , Singer PA , Siegler M , Johnson FL . Bone marrow transplantation for sickle cell disease. A study of patients’ decisions . N Engl J Med . 1991;325:1349–1353
  38. Verburg RJ , Sont JK , Vliet Vlieland TP , et al.   High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis . J Rheumatol . 2001;28:719–727
  39. Bredeson CN , Pavletic SZ . Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease . Best Pract Res Clin Haematol . 2004;17:327–343
  40. Baron F , Maris MB , Storer BE , et al.   High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation . Leukemia . 2005;19:822–828
  41. Flowers MED , Parker PM , Johnston LJ , et al.   Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients (long-term follow-up of a randomized trial) . Blood . 2002;100:415–419
  42. Oehler VG , Radich JP , Storer B , et al.   Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia . Biol Blood Marrow Transplant . 2005;11:85–92
  43. Stem Cell Trialists’ Collaborative Group . Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies (an individual patient data meta-analysis of nine randomized trials) . J Clin Oncol . 2005;23:5074–5087
  44. Miller KB , Roberts TF , Chan G , et al.   A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease . Bone Marrow Transplant . 2004;33:881–889
  45. Fowler D , Hou J , Foley J , et al.   Phase I clinical trial of donor T-helper type-2 cells after immunoablative, reduced intensity allogeneic PBSC transplant . Cytotherapy . 2002;4:429–430
  46. Petersdorf EW , Anasetti C , Martin PJ , et al.   Limits of HLA mismatching in unrelated hematopoietic cell transplantation . Blood . 2004;104:2976–2980
  47. Petersdorf EW . HLA matching in allogeneic stem cell transplantation . Curr Opin Hematol . 2004;11:386–391
  48. Caillat-Zucman S , Le Deist F , Haddad E , et al.   Impact of HLA matching on outcome of hematopoietic stem cell transplantation in children with inherited diseases (a single-center comparative analysis of genoidentical, haploidentical or unrelated donors) . Bone Marrow Transplant . 2004;33:1089–1095
  49. Hurley CK , Baxter Lowe LA , Logan B , et al.   National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants . Biol Blood Marrow Transplant . 2003;9:610–615
  50. Kollman C , Abella E , Baitty RL , et al.   Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors . Transplantation . 2004;78:89–95
  51. Canals C , Martino R , Sureda A , et al.   Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients (comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection) . Exp Hematol . 2003;31:1039–1043
  52. Cornelissen JJ , van der Holt B , Petersen EJ , et al.   A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies . Exp Hematol . 2003;31:855–864
  53. Bishop MR , Fowler DH , Marchigiani D , et al.   Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer . J Clin Oncol . 2004;22:3886–3892
  54. Antin JH , Childs R , Filipovich AH , et al.   Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation (recommendations from a workshop at the 2001 tandem meetings) . Biol Blood Marrow Transplant . 2001;7:473–485
  55. Carvallo C , Geller N , Kurlander R , et al.   Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors . Blood . 2004;103:1560–1563
  56. Baron F , Little M-T , Storb R . Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning . Blood Rev . 2005;19:153–164
  57. Marmont AM , Gualandi F , van Lint MT , Bacigalupo A . Refractory Evans’ syndrome treated with allogeneic SCT followed by DLI. Demonstration of graft-versus-autoimmunity effect . Bone Marrow Transplant . 2003;31:399–402
  58. Passweg JR , Rabusin M , Musso M , et al.   Haematopoietic stem cell transplantation for refractory autoimmune cytopenia . Br J Haematol . 2004;125:749–755

 The opinions expressed are those of the authors and do not represent the position of the National Institute of Allergy and Infectious Diseases, the National Cancer Institute, the National Institutes of Health, or the US Government.

PII: S1083-8791(05)00460-X

doi: 10.1016/j.bbmt.2005.07.009

Biology of Blood and Marrow Transplantation
Volume 11, Issue 11 , Pages 862-870 , November 2005

Article Tools